血清HE4和CA125联合检测在卵巢癌诊断中的应用分析  

Clinical Value of Combined Detection of Serum HE4 and CA125 in Diagnosis of Ovarian Cancer

作　　者：陈少林 常璠 祁云清 

机构地区：[1]西宁市第三人民医院核医学科,青海西宁810005

出　　处：《标记免疫分析与临床》2012年第1期6-8,共3页Labeled Immunoassays and Clinical Medicine

摘　　要：目的探讨血清人附睾蛋白4(HE4)和糖类抗原125(CA125)水平联合检测在卵巢癌诊断中的应用价值。方法对85例卵巢癌组患者、55例盆腔良性疾病组患者和120名对照组用ELISA测定血清HE4水平,用ECLIA测定CA125水平。结果卵巢癌组血清HE4水平与对照组比较明显升高,差异有明显统计学意义(P<0.001),而盆腔良性疾病组血清HE4水平与对照组比较,差异无统计学意义(P>0.05)。在卵巢癌组及盆腔良性疾病组血清CA125水平均升高,与对照组比较,差异有统计学意义(P<0.001)。结论结果表明,HE4和CAl25是较理想的卵巢癌肿瘤标志物,其血清水平对卵巢肿瘤的良恶性辅助诊断及鉴别诊断有一定的临床价值,可提高对卵巢癌的诊断能力。Objective To explore the application values of the combined detection of serum HE4 and CA125 level in diagnosis of ovarian cancer. Methods The serum HE4 and CA125 levels in 85 patients with ovarian cancer, 55 patients with benign pelvic diseases and 120 healthy controls were determined by ELISA and ECLIA, respectively. Results It showed that the serum HE4 level in patients with ovarian cancer was signifi- cantly higher than that of healthy controls （ P 〈 0. 001 ）. There was no significantly difference on serum HE4 level between patients with benign pelvic diseases and healthy controls （ P 〉 0.05 ） patients either with ovarian cancer or with benign pelvic diseases were significantly controls （P 〈 O. 001 ）. Conclusion value in the differential diagnosis of The combined detection of serum HEA magnificent or benign ovarian tumors. The serum CA125 levels in higher than that of healthy and CA125 have significant clinical

关 键 词：卵巢癌 盆腔良性疾病 人附睾蛋白4 糖类抗原125 联合检测 酶联免疫法 电化学发光免疫法 

分 类 号：R737.31[医药卫生—肿瘤]